Ed Miseta

Ed Miseta

Ed Miseta is chief editor for the website Clinical Leader, executive editor for Life Science Leader magazine, conference chair for Clinical Leader Forum, and host of Clinical Leader Live. Ed studied Business Economics at The Pennsylvania State University and also holds a Master’s degree in Business Administration. Ed has been a writer for more than 12 years and has been covering clinical research since January 2013. Ed spent 10 years in banking and investments and also taught economics at Penn State for 8 years. In his current position, Ed interviews clinical executives from pharmaceutical and biotech companies and shares their insights with readers. His primary focus is on best practices, challenges faced and overcome, clinical trends, partnering, and implementing new technologies. He has also moderated numerous speaker panels at industry conferences and trade shows.


  • How Janssen Uses Technology To Create Patient-Centric Trials

    New and emerging technologies are impacting clinical trials in many ways, but nowhere is that more apparent than in the area of patient centricity. Janssen is attempting to overcome trial challenges using technology and a three-pronged approach.

  • AstraZeneca’s Patient Centric Approach To Chronic Kidney Disease

    When it comes to clinical trials, pharmaceutical companies historically have focused on what the FDA needs to see to support approval. But there can be a gap between what companies demonstrate to the FDA and how that transpires into the real-world setting. Dr. Kerry Cooper believes this is a challenge pharmaceutical companies must overcome by continued evidence generation that can relate to their patient populations.

  • Is Your Clinical Trial Ready To Go Digital?

    Digital clinical trials are a popular topic in the life sciences industry. But for all the talk we hear about the use of wearable devices in trials, it’s often hard to gauge exactly how many companies are using these devices.

  • What I Learned At AbbVie’s Development Design Center

    In July 2019 I had the opportunity to visit the AbbVie campus in North Chicago. My purpose for being there was to tour the company’s Development Design Center (DDC), which provided a detailed look into what AbbVie sees as the future of clinical trials.

  • What Do Sponsors And CROs Think About Technology Use In Trials?

    Each year, The Avoca Group surveys industry professionals to understand trends in clinical development. For one of its most recent surveys, Avoca examined what sponsors and CROs think about innovation and the use of technology in clinical trials.

  • The Keys To A Successful Training, Change Management, & Support Program

    Implementing a new technology presents many challenges for companies. There is the implementation itself, the training of users, managing the change, and finally providing support to users. A panel discussion at the 2019 Oracle Health Sciences Connect conference tackled these challenges, providing advice on how to manage all facets of a new technology implementation.

  • Rebiotix Works With Regulators To Define A New Clinical Pathway

    Rebiotix, a Ferring company, hopes to revolutionize the treatment of debilitating diseases by harnessing the power of the human microbiome. The company is developing their proprietary MRT drug platform, which uses a defined manufacturing process and quality control parameters to assess the impact of human-derived microbiota therapies on patient health and disease.

  • AbbVie Goes All-In On Wearables And Digital Technologies

    When working groups at AbbVie first began evaluating the use of digital technologies in clinical trials, the discussions were mostly conceptual. Individuals agonized over the right approach, the quality of the data, and whether the efforts would be accepted by regulators. Three years ago, the company decided to stop debating and start executing.

  • GenSight Uses Gene Therapies To Target Neurodegenerative Diseases

    GenSight Biologics believes it is on the cutting edge of ophthalmology, gene therapy, and drug development. The company is focused on finding treatments for patients with neurodegenerative diseases and is developing products that are a combination of gene therapy, its mitochondrial targeting sequence technology, and optogenetics.

  • Lupus Community Tackles Treatment & Clinical Trial Barriers

    Few treatments have been approved for Lupus and the industry has seen many failed clinical trials. Variations in care worldwide, as well as poor overall access to care, has also hampered efforts to bring relief to patients. For those reasons, the international lupus community has come together to conduct a study aimed at identifying clinical and treatment barriers that must be overcome.

More From Ed Miseta